In order to resolve this conflict, this meta-analysis of 39 eligible studies including 5,817 cases and 6,544 controls for CYP1A2*F (from 13 studies), 9,219 cases and 10,406 controls for CYP1B1 Leu432Val (from 12 studies), 6,840 cases and 7,761 controls for CYP1B1 Asn453Ser (from 8 studies), and 4,302 cases and 4,791 controls for CYP1B1 Arg48Gly (from 6 studies) was performed to derive a more precise estimation of the association between CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms and risk of colorectal cancer. This evidence concerns the gene CYP1B1 and colorectal cancer.